You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrisalicylate-choline
Accession NumberDB01401
TypeSmall Molecule
GroupsApproved
DescriptionCholine magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28%.(PMID: 1728115, 1618240)
Structure
Thumb
Synonyms
Tricosal
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIDJJ95FJP1H
CAS numberNot Available
WeightAverage: 539.814
Monoisotopic: 539.164188051
Chemical FormulaC26H29MgNO10
InChI KeyFQCQGOZEWWPOKI-UHFFFAOYSA-K
InChI
InChI=1S/3C7H6O3.C5H14NO.Mg/c3*8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7;/h3*1-4,8H,(H,9,10);7H,4-5H2,1-3H3;/q;;;+1;+2/p-3
IUPAC Name
magnesium(2+) ion (2-hydroxyethyl)trimethylazanium tris(2-hydroxybenzoate)
SMILES
[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
Pharmacology
IndicationCholine magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis. This medication is also used to treat fever in adults.
Structured Indications Not Available
PharmacodynamicsTrisalicylate-choline is a non-steroidal anti-inflammatory drug (NSAID) that contains a combination of choline salicylate and magnesium salicylate. Does not affect platelet aggregation.
Mechanism of actionInhibits prostaglandin synthesis; acts on the hypothalamus heat-regulating center to reduce fever; blocks the generation of pain impulses
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinunknown
inhibitor
HumanP35354 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationrenal
Half lifeNot Available
ClearanceNot Available
ToxicitySalicylate intoxication, known as salicylism, may occur with large doses or extended therapy. Common symptoms of salicylism include headache, dizziness, tinnitus, hearing impairment, confusion, drowsiness, sweating, vomiting, diarrhea, and hyperventilation. A more severe degree of salicylate intoxication can lead to CNS disturbances, alteration in electrolyte balance, respiratory and metabolic acidosis, hyperthermia, and dehydration.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Trisalicylate-choline Action PathwayDrug actionSMP00703
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 5-androstenedione.Experimental, Illicit
AbciximabTrisalicylate-choline may increase the anticoagulant activities of Abciximab.Approved
AcebutololTrisalicylate-choline may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Aceclofenac.Approved
AcenocoumarolTrisalicylate-choline may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Trisalicylate-choline.Approved, Vet Approved
AclarubicinTrisalicylate-choline may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Trisalicylate-choline.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Alendronic acid.Approved
AliskirenTrisalicylate-choline may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololTrisalicylate-choline may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Trisalicylate-choline.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Amcinonide.Approved
AmikacinTrisalicylate-choline may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTrisalicylate-choline may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinTrisalicylate-choline may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTrisalicylate-choline may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Anisodamine.Investigational
annamycinTrisalicylate-choline may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Antipyrine.Approved
Antithrombin III humanTrisalicylate-choline may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Trisalicylate-choline may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanTrisalicylate-choline may increase the anticoagulant activities of Apixaban.Approved
ApramycinTrisalicylate-choline may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Apremilast.Approved, Investigational
ArbekacinTrisalicylate-choline may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinTrisalicylate-choline may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanTrisalicylate-choline may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTrisalicylate-choline may decrease the antihypertensive activities of Arotinolol.Approved
AtenololTrisalicylate-choline may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trisalicylate-choline.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Trisalicylate-choline.Approved
BalsalazideTrisalicylate-choline may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminTrisalicylate-choline may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTrisalicylate-choline may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Trisalicylate-choline.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Trisalicylate-choline.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Trisalicylate-choline.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Betamethasone.Approved, Vet Approved
BetaxololTrisalicylate-choline may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Betulinic Acid.Investigational
BevantololTrisalicylate-choline may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Trisalicylate-choline.Approved, Investigational
BisoprololTrisalicylate-choline may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTrisalicylate-choline may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTrisalicylate-choline may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trisalicylate-choline.Approved
BucillamineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Bucillamine.Investigational
BucindololTrisalicylate-choline may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Budesonide.Approved
BufuralolTrisalicylate-choline may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideTrisalicylate-choline may decrease the diuretic activities of Bumetanide.Approved
BupranololTrisalicylate-choline may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Trisalicylate-choline.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Trisalicylate-choline.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Trisalicylate-choline.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Trisalicylate-choline.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Trisalicylate-choline.Approved, Vet Approved, Withdrawn
CarteololTrisalicylate-choline may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTrisalicylate-choline may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Celecoxib.Approved, Investigational
CeliprololTrisalicylate-choline may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTrisalicylate-choline may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Trisalicylate-choline.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Trisalicylate-choline.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Trisalicylate-choline.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Trisalicylate-choline.Approved
CinoxacinTrisalicylate-choline may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidTrisalicylate-choline may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Trisalicylate-choline.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Curcumin.Investigational
CyclosporineTrisalicylate-choline may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with D-Limonene.Investigational
Dabigatran etexilateTrisalicylate-choline may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTrisalicylate-choline may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTrisalicylate-choline may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinTrisalicylate-choline may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinTrisalicylate-choline may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Trisalicylate-choline.Approved
DextranTrisalicylate-choline may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Trisalicylate-choline may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Trisalicylate-choline may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Trisalicylate-choline may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Trisalicylate-choline.Approved, Vet Approved
DicoumarolTrisalicylate-choline may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Trisalicylate-choline.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trisalicylate-choline.Approved
DihydrostreptomycinTrisalicylate-choline may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Trisalicylate-choline.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Trisalicylate-choline.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Trisalicylate-choline.Approved
DoxorubicinTrisalicylate-choline may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTrisalicylate-choline may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ebselen.Investigational
Edetic AcidTrisalicylate-choline may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTrisalicylate-choline may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Trisalicylate-choline.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Trisalicylate-choline.Approved
EnoxacinTrisalicylate-choline may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinTrisalicylate-choline may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Epirizole.Approved
EpirubicinTrisalicylate-choline may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTrisalicylate-choline may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Trisalicylate-choline.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trisalicylate-choline.Approved
EquileninThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Equilin.Approved
EsmololTrisalicylate-choline may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Estrone sulfate.Approved
Etacrynic acidTrisalicylate-choline may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Trisalicylate-choline.Approved, Investigational
Ethyl biscoumacetateTrisalicylate-choline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Trisalicylate-choline.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Trisalicylate-choline.Vet Approved
FleroxacinTrisalicylate-choline may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Trisalicylate-choline.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fludrocortisone.Approved
FluindioneTrisalicylate-choline may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTrisalicylate-choline may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Trisalicylate-choline.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Trisalicylate-choline.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Trisalicylate-choline.Approved, Nutraceutical, Vet Approved
FondaparinuxTrisalicylate-choline may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTrisalicylate-choline may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Trisalicylate-choline.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Trisalicylate-choline.Approved
FramycetinTrisalicylate-choline may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTrisalicylate-choline may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTrisalicylate-choline may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTrisalicylate-choline may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Trisalicylate-choline.Approved, Withdrawn
GemifloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTrisalicylate-choline may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTrisalicylate-choline may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATrisalicylate-choline may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with HE3286.Investigational
HeparinTrisalicylate-choline may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Higenamine.Investigational
HirulogTrisalicylate-choline may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with HMPL-004.Investigational
HydralazineTrisalicylate-choline may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Trisalicylate-choline.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Trisalicylate-choline.Approved
Hygromycin BTrisalicylate-choline may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Trisalicylate-choline.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Icatibant.Approved
IdarubicinTrisalicylate-choline may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxTrisalicylate-choline may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Trisalicylate-choline.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Trisalicylate-choline.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Trisalicylate-choline.Approved
IndenololTrisalicylate-choline may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Trisalicylate-choline.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Indoprofen.Withdrawn
INNO-206Trisalicylate-choline may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trisalicylate-choline.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Istaroxime.Investigational
KanamycinTrisalicylate-choline may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Trisalicylate-choline.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Trisalicylate-choline.Approved
LabetalolTrisalicylate-choline may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Trisalicylate-choline.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Trisalicylate-choline.Approved, Investigational
LepirudinTrisalicylate-choline may increase the anticoagulant activities of Lepirudin.Approved
LevobunololTrisalicylate-choline may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Trisalicylate-choline.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Trisalicylate-choline.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Trisalicylate-choline.Approved
LomefloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Trisalicylate-choline.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Trisalicylate-choline.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Trisalicylate-choline.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trisalicylate-choline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Trisalicylate-choline.Approved
ME-609The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trisalicylate-choline.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Trisalicylate-choline.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Trisalicylate-choline.Approved, Vet Approved
MesalazineTrisalicylate-choline may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trisalicylate-choline.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Trisalicylate-choline.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTrisalicylate-choline may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Trisalicylate-choline.Approved
MetoprololTrisalicylate-choline may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTrisalicylate-choline may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Trisalicylate-choline.Approved
MizoribineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Trisalicylate-choline.Approved
MometasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Trisalicylate-choline.Approved
MoxifloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trisalicylate-choline.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trisalicylate-choline.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nabumetone.Approved
NadololTrisalicylate-choline may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTrisalicylate-choline may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTrisalicylate-choline may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Trisalicylate-choline.Approved
Nalidixic AcidTrisalicylate-choline may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Trisalicylate-choline.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with NCX 4016.Investigational
NeamineTrisalicylate-choline may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinTrisalicylate-choline may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTrisalicylate-choline may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nepafenac.Approved
NetilmicinTrisalicylate-choline may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nitroaspirin.Investigational
NorfloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Trisalicylate-choline.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trisalicylate-choline.Approved
OlsalazineTrisalicylate-choline may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Trisalicylate-choline.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Orgotein.Vet Approved
OtamixabanTrisalicylate-choline may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trisalicylate-choline.Approved
OxprenololTrisalicylate-choline may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Parecoxib.Approved
ParomomycinTrisalicylate-choline may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTrisalicylate-choline may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateTrisalicylate-choline may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Trisalicylate-choline.Approved
PhenindioneTrisalicylate-choline may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonTrisalicylate-choline may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Trisalicylate-choline.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trisalicylate-choline.Approved, Investigational
PindololTrisalicylate-choline may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinTrisalicylate-choline may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTrisalicylate-choline may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trisalicylate-choline.Approved, Investigational
PlicamycinTrisalicylate-choline may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Trisalicylate-choline.Approved
PractololTrisalicylate-choline may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Trisalicylate-choline.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Trisalicylate-choline can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Propacetamol.Approved
PropranololTrisalicylate-choline may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Trisalicylate-choline.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Trisalicylate-choline.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Trisalicylate-choline.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Trisalicylate-choline.Vet Approved
Protein CTrisalicylate-choline may increase the anticoagulant activities of Protein C.Approved
Protein S humanTrisalicylate-choline may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTrisalicylate-choline may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with PTC299.Investigational
PuromycinTrisalicylate-choline may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Trisalicylate-choline.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Trisalicylate-choline.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Trisalicylate-choline.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Trisalicylate-choline.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Resveratrol.Experimental, Investigational
ReviparinTrisalicylate-choline may increase the anticoagulant activities of Reviparin.Approved
RibostamycinTrisalicylate-choline may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Risedronate.Approved, Investigational
RivaroxabanTrisalicylate-choline may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinTrisalicylate-choline may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Trisalicylate-choline.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Trisalicylate-choline.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Trisalicylate-choline.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trisalicylate-choline.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Trisalicylate-choline.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Seratrodast.Approved, Investigational
SisomicinTrisalicylate-choline may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolTrisalicylate-choline may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTrisalicylate-choline may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinTrisalicylate-choline may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Trisalicylate-choline.Approved
SpironolactoneTrisalicylate-choline may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with SRT501.Investigational
StreptomycinTrisalicylate-choline may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTrisalicylate-choline may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineTrisalicylate-choline may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Trisalicylate-choline.Approved
SulodexideTrisalicylate-choline may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Trisalicylate-choline.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Trisalicylate-choline.Approved, Withdrawn
TacrolimusTrisalicylate-choline may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Trisalicylate-choline.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Trisalicylate-choline.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Trisalicylate-choline.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trisalicylate-choline.Approved, Investigational
TemafloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Trisalicylate-choline.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Trisalicylate-choline.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tiludronate.Approved, Vet Approved
TimololTrisalicylate-choline may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tixocortol.Approved
TobramycinTrisalicylate-choline may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Trisalicylate-choline.Approved
TorasemideTrisalicylate-choline may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Trisalicylate-choline.Approved
TranilastThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Trisalicylate-choline.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Trisalicylate-choline.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTrisalicylate-choline may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Trisalicylate-choline.Approved, Vet Approved
TrovafloxacinTrisalicylate-choline may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Trisalicylate-choline.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinTrisalicylate-choline may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Trisalicylate-choline.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Trisalicylate-choline.Approved
WarfarinTrisalicylate-choline may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTrisalicylate-choline may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Trisalicylate-choline may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Trisalicylate-choline.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Zomepirac.Withdrawn
ZorubicinTrisalicylate-choline may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9852
Blood Brain Barrier-0.8993
Caco-2 permeable+0.5436
P-glycoprotein substrateSubstrate0.7681
P-glycoprotein inhibitor INon-inhibitor0.9522
P-glycoprotein inhibitor IINon-inhibitor0.6479
Renal organic cation transporterNon-inhibitor0.7147
CYP450 2C9 substrateNon-substrate0.7398
CYP450 2D6 substrateNon-substrate0.7764
CYP450 3A4 substrateSubstrate0.588
CYP450 1A2 substrateNon-inhibitor0.7658
CYP450 2C9 inhibitorNon-inhibitor0.8703
CYP450 2D6 inhibitorNon-inhibitor0.7642
CYP450 2C19 inhibitorNon-inhibitor0.8941
CYP450 3A4 inhibitorNon-inhibitor0.9072
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9752
Ames testNon AMES toxic0.7389
CarcinogenicityNon-carcinogens0.729
BiodegradationReady biodegradable0.5807
Rat acute toxicity2.3576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8568
hERG inhibition (predictor II)Non-inhibitor0.7428
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Choline mag trisal 1 gm tablet1.23USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Choline mag trisal 500 mg tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP1.98ChemAxon
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Benzoic acid
  • Benzoyl
  • Phenol
  • Choline
  • Vinylogous acid
  • Quaternary ammonium salt
  • 1,2-aminoalcohol
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Organic salt
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic zwitterion
  • Aromatic homomonocyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Nizankowska E, Dworski R, Soja J, Szczeklik A: Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients. Clin Exp Allergy. 1990 Nov;20(6):647-52. [PubMed:2083404 ]
  2. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616 ]
  3. Schwartz KA: Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. Adv Clin Chem. 2006;42:81-110. [PubMed:17131625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616 ]
  2. Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79. [PubMed:17033106 ]
  3. Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60. [PubMed:17037745 ]
  4. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71. [PubMed:17181859 ]
  5. Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16. [PubMed:17258197 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:07 / Updated on August 17, 2016 12:23